Sensitivity of magnetic resonance imaging of dendritic cells for in vivo tracking of cellular cancer vaccines

✍ Scribed by Pauline Verdijk; Tom W.J. Scheenen; W. Joost Lesterhuis; Giulio Gambarota; Andor A. Veltien; Piotr Walczak; Nicole M. Scharenborg; Jeff W.M. Bulte; Cornelis J.A. Punt; Arend Heerschap; Carl G. Figdor; I. Jolanda M. de Vries

• Publisher: John Wiley and Sons
• Year: 2006
• Tongue: French
• Weight: 365 KB
• Volume: 120
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.22385

✦ Synopsis

Abstract

Success of immunotherapy with dendritic cells (DC) to treat cancer is highly dependent on their interaction with and activation of antigen specific T cells. To maximize DC–T cell contact accurate delivery of the therapeutic cells into the lymph node, or efficient trafficking of DC to the lymph nodes of the patient is essential. Since responses are seen in some patients but not in others, monitoring of the injected cells may be of major importance. Tracking of cells with magnetic resonance (MR) imaging is a non‐invasive method that provides detailed anatomical information and is therefore more informative for the evaluation of the localization of therapeutic cells after injection than e.g. scintigraphic imaging. To challenge the sensitivity of this novel technique, we investigated the minimum amount of label and the number of cells required for MR imaging and the effect of labeling on DC function. DC were labeled with different concentrations of a clinically approved MR contrast agent consisting of superparamagnetic iron oxide particles and were imaged at both 3 and 7 T. Our results demonstrate the following: (i) When loaded with 30 (±4) pg Fe/cell, cell numbers as low as 1,000 cells/mm^3^ at 3 T and 500 cells/mm^3^ at 7 T could be readily imaged; (ii) Labeling does not affect cell viability and function; (iii) Because of its high spatial resolution and sensitivity, MRI is ideally suited to track therapeutic cells in vivo. © 2006 Wiley‐Liss, Inc.